Portal de Periódicos da CAPES

Neostriatal Dopamine Uptake and Reversal of Age‐related Movement Disorders with Dopamine‐Uptake Inhibitorsa

1988; Wiley; Volume: 515; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1988.tb33006.x

1749-6632

C. Anthony Altar, John F. Marshall,

Parkinson's Disease Mechanisms and Treatments

Annals of the New York Academy of SciencesVolume 515, Issue 1 p. 343-354 Neostriatal Dopamine Uptake and Reversal of Age-related Movement Disorders with Dopamine-Uptake Inhibitorsa C. ANTHONY ALTAR, C. ANTHONY ALTAR Research Department, CIBA-GEIGY Pharmaceuticals Division, Summit, New Jersey 07901Search for more papers by this authorJOHN F. MARSHALL, JOHN F. MARSHALL Department of Psychobiology, University of California, Irvine, California 92717Search for more papers by this author C. ANTHONY ALTAR, C. ANTHONY ALTAR Research Department, CIBA-GEIGY Pharmaceuticals Division, Summit, New Jersey 07901Search for more papers by this authorJOHN F. MARSHALL, JOHN F. MARSHALL Department of Psychobiology, University of California, Irvine, California 92717Search for more papers by this author First published: January 1988 https://doi.org/10.1111/j.1749-6632.1988.tb33006.xCitations: 17 a This research was supported by USPHS Grant Nos. AG 00538 and NS 20122 to J. F. Marshall. C. A. Altar was supported in part by USPHS Training Grant No. AG 00096. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Demarest, J. T., G. D. Reigle & K. E. Moore 1980. Characteristics of dopaminergic neurons in the aged male rat. Neuroendocrinology 31: 222–227. 2 Osterburg, H. H., H. G. Donahue, J. A. Severson & C. E. Finch 1981. Catecholamine levels and turnover during aging in brain regions of male C57 BL/6J mice. Brain Res. 224: 337–352. 3 Strong, R., T. Samorajski & Z. Gottesfeld 1982. Regional mapping of neostriatal neurotransmitter systems as a function of aging. J. Neurochem. 39: 831–836. 4 Joseph, J. A., R. E. Berger, B. T. Engel & G. S. Roth 1978. Age-related changes in the nigrostriatum: A behavioral and biochemical analysis. J. Gerontol. 33: 643–649. 5 Severson, J. A. & C. E. Finch 1980. Reduced dopaminergic binding during aging in the rodent striatum. Brain Res. 199: 147–162. 6 O'Boyle, K. M. & J. L. Waddington 1984. Loss of rat striatal dopamine receptors with aging is selective for D-2 but not D-1 sites. Eur. J. Pharmacol. 105: 171–174. 7 Carlsson, A. & B. Winblad 1976. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm. 38: 171–176. 8 Riederer, P. & St. Wuketich 1976. Time course of nigro-striatal degeneration in Parkinson's disease. J. Neural Transm. 38: 277–301. 9 Severson, J. A., J. Marcusson, B. Winblad & C. E. Finch 1982. Age correlated loss of dopaminergic binding sites in human basal ganglia. J. Neurochem. 39: 1623–1631. 10 Lytle, L. D. & C. A. Altar 1979. Diet, central nervous system, and aging. Fed. Proc. Fed. Am. Soc. Exp. Biol. 38: 2017–2022. 11 Finch, C. E., P. K. Randall & J. F. Marshall 1981. Aging and basal ganglia functions. In Annual Rev. Gerontol. Geriatr. Vol. 2. C. Eisdorfer, Ed.: 49–85. 12 Gage, G. H., S. B. Dunnett, U. Stenevi & A. Björklund 1983. Aged rats: Recovery of motor impairments by intrastriatal nigral grafts. Science 221: 966–969. 13 Joseph, J. A., R. T. Bartus, D. Clody, D. Morgan, C. Finch, B. Beer & S. Sesack 1983. Psychomotor performance in the senescent rodent: Reduction of deficits via striatal dopamine receptor up-regulation. Neurobiol. Aging 4: 313–319. 14 Marshall, J. F. & N. Berrios 1979. Movement disorders of aged rats: reversal by dopamine receptor stimulation. Science 206: 477–479. 15 Iversen, L. L. 1974. Uptake mechanism for neurotransmitter amines. Biochem. Pharmacol. 23: 1927–1935. 16 Thompson, J. M., J. R. Whitaker & J. A. Joseph 1981. [3H]Dopamine accumulation and release from striatal slices in young, mature, and senescent rats. Brain Res. 224: 436–440. 17 Strong, R., T. Samorajski & Z. Gottesfeld 1984. High affinity uptake of neurotransmitters in rat neostriatum: effects of aging. J. Neurochem. 43: 1766–1768. 18 Jonec, V. & C. E. Finch 1975. Aging and dopamine uptake by subcellular fractions of the C57BL/6J male mouse brain. Brain Res. 91: 197–215. 19 Tennyson, V. M., R. E. Barrett, G. Cohen, L. Coté, R. Heikkila & C. Mytilineou 1972. The developing neostriatum of the rabbit: correlation of fluorescence histochemistry, electron microscopy, endogenous dopamine levels, and [3H]dopamine uptake. Brain Res. 46: 251–285. 20 Bell, L. J., L. L. Iversen & N. J. Uretsky 1970. Time course of the effects of 6-hydroxydopamine on catecholamine-containing neurons in rat hypothalamus and striatum. Br. J. Pharmacol. 40: 790–799. 21 Altar, C. A., S. O'Neil & J. F. Marshall 1984. Sensorimotor impairment and elevated levels of dopamine metabolites in the neostriatum occur rapidly after intranigral injections of 6-hydroxydopamine or gamma-hydroxybutyrate in awake rats. Neuropharmacology 23: 309–318. 22 Altar, C. A., M. R. Marien & J. F. Marshall 1987. Time course of adaptation in dopamine synthesis, metabolism and release following nigrostriatal lesions: Implications for behavioral recovery from brain injury. J. Neurochem. 48: 390–399. 23 Refshauge, C., P. T. Kissinger, R. Dreiling, R. Freeman & R. N. Adams 1974. New high performance liquid chromatographic analysis of brain catecholamines. Life Sci. 14: 311–322. 24 Bradford, M. M. 1976. A rapid and sensitive model for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248–254. 25 Coyle, J. T. & J. Axelrod 1983. Development of the uptake and storage of L-[3H]norepinephrine in the rat brain. J. Neurochem. 18: 2061–2075. 26 McNeill, T. H., L. L. Koek & J. W. Haycock 1984. Age-correlated changes in dopaminergic nigrostriatal perikarya of the C57 BL/6NNia mouse. Mech. Ageing Dev. 24: 293–307. 27 Memo, M., L. Lucchi, P. F. Spano & M. Trabucchi 1980. Aging process affects a single class of dopamine receptors. Brain Res. 202: 488–492. 28 Reis, D. J., R. A. Ross & T. H. Joh 1977. Changes in the activity and amounts of enzymes synthesizing catecholamines and acetylcholine in brain, adrenal medulla, and sympathetic ganglia of aged rat and mouse. Brain Res. 136: 465–474. 29 Cooper, B. R., T. J. Hester & R. A. Maxwell 1980. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): Evidence for selective blockade of dopamine uptake in vivo. J. Pharmacol. Exp. Ther. 215: 127–134. 30 Hunt, P., M-H. Kannengiesser & J-P. Raynaud 1974. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J. Pharm. Pharmacol. 26: 370–371. 31 Ross, S. B. 1979. The central stimulatory action of inhibitors of the dopamine uptake. Life Sci. 24: 159–168. 32 Samanin, R., S. Bernasconi & S. Garattini 1975. The effect of nomifensine on the depletion of brain serotonin and catecholamines induced respectively by fenfluramine and 6-hydroxydopamine in rats. Eur. J. Pharmacol. 34: 377–380. 33 Soroko, F. E., N. B. Mehta, R. A. Maxwell, R. M. Ferris & D. H. Schroeder 1977. Bupropion hydrochloride [(±)α-t-butylamino-3-chloropropiophenone HCI]: a novel antidepressant agent. J. Pharm. Pharmacol. 29: 767–770. 34 Schacht, U. & W. Heptner 1974. Effect of nomifensine (HOE 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes. Biochem. Pharmacol. 23: 3413–3422. 35 Bernheimer, H., W. Birkmayer, O. Hornykiewicz, K. Jellinger & F. Seitilberger Brain dopamine and the syndromes of Parkinsonism and Huntington: Clinical, morphological, and neurochemical correlations. J. Neurol. Sci. 20: 415–455. 36 Mortimer, J. A. & D. D. Webster 1982. Comparison of extrapyramidal motor function in normal aging and Parkinson's disease. In The Aging Motor System. J. A. Mortimer, F. J. Pirozzola, & G. J. Masetta, Eds.: 217–241. Praeger. New York . 37 Goetz, C. G., C. M. Tanner & H. L. Klawans 1984. Bupropion in Parkinson's disease. Neurology 34: 1092–1094. 38 Delwaide, P. J., P. Martinelli & J. Schoenen 1983. Mazindol in the treatment of Parkinson's disease. Arch. Neurol. 40: 788–790. 39 Neve, K. A., M. R. Kozlowski & J. F. Marshall 1982. Plasticity of neostriatal dopamine receptors after nigro-striatal injury: Relationship to recovery of sensorimotor functions and behavioral supersensitivity. Brain Res. 244: 33–44. 40 Hökfelt, T. & U. Ungerstedt 1973. Specificity of 6-hydroxydopamine-induced degeneration of central monoamine neurones: An electron and fluorescence microscopic study with special reference to intracerebral injection of the nigro-striatal dopamine system. Brain Res. 60: 269–297. 41 Marshall, J. F. & C. A. Altar 1986. Striatal dopamine uptake and swim performance of the aged rat. Brain Res. 379: 112–117. Citing Literature Volume515, Issue1Central Determinants of Age‐Related Declines in Motor FunctionJanuary 1988Pages 343-354 ReferencesRelatedInformation